Palmoplantar pustulosis with severe psoriatic nail dystrophy in a patient receiving etanercept for treatment of ankylosing spondylitis

Wang, Sheng Pei; Wu, Chien-Sheng; Lu, Po Hsuan

doi:10.1016/j.dsi.2017.04.008

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A summary of demographics of the 155 patients with biologic‐associated PPP and PPPP are shown in Table 1 8,11,12,14–63 . Overall, the mean age was 44.1 (range: 22–79), with a female preponderance (71.6%, n = 53, not reported [NR, n = 81]), which was similar between patients with biologic‐associated PPP and PPPP (42.3 years and 69% female vs. 45 years and 73.3% female, respectively).…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review

Mufti

Zaaroura

et al. 2022

Int J Dermatology

View full text Add to dashboard Cite

Background Palmoplantar pustulosis (PPP) and palmoplantar pustular psoriasis (PPPP) are chronic inflammatory skin conditions characterized by eruptions of sterile pustules on the palms and/or soles. Biologic use has been associated with PPP and PPPP development in the literature.Objectives To identify PPP and PPPP associated with biologics and summarize reported treatments and outcomes.Methods We systematically searched in MEDLINE and Embase for articles that reported PPP or PPPP during biologic treatment. After a full-text review, 53 studies were included for analysis. ResultsWe identified 155 patients with PPP/PPPP onset during biologic treatment, with a mean age of 44.1 years and a female preponderance (71.6%). The most frequently reported biologics were adalimumab (43.9%) and infliximab (33.3%). IL-17 inhibitors, secukinumab (7.6%) and brodalumab (1.5%), were reported only in association with PPPP.Overall, 58.8% of patients had complete remission (CR) in 3.6 months and 23.5% had partial remission (PR) in 3.7 months. The most common treatments that led to CR were topical corticosteroids (n = 16) and biologic switching (n = 8).Conclusions Clinicians should anticipate PPP or PPPP as potential drug reactions to biologics such as adalimumab and infliximab. Large-scale studies are required to confirm our findings and further explore the pathogenesis for biologic-associated PPP and PPPP.

show abstract

Section: Resultsmentioning

confidence: 98%

“…After the removal of duplicates, 377 articles were screened and 172 were excluded, leading to 205 full‐text articles accessed for eligibility. A total of 53 articles met inclusion criteria for this qualitative synthesis 8,11,12,14–63 …”

Section: Resultsmentioning

confidence: 99%